PTGX Q2 2021 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-63.6% YoY

Gross Profit

$2M100.0% margin

Operating Income

-$31M-1363.4% margin

Net Income

-$31M-1361.7% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-63.4%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$404M

Total Liabilities

$47M

Stockholders' Equity

$357M

Cash & Equivalents

$192M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$6M	-63.6%
Gross Profit	$2M	$6M	-63.6%
Operating Income	-$31M	-$18M	-69.5%
Net Income	-$31M	-$19M	-58.8%

Revenue Segments

License And Collaborative Revenue

$96M100%

Financial Service Other

$200,0000%